September 4, 2025
Company name: | Pharma Foods International Co., Ltd. |
Representative: | Mujo Kim, President |
(Securities code: 2929 Prime Market) | |
Inquiries: | Seiyu Harada, General Manager of Corporate Strategy Department |
(Telephone: +81-75-394-8600) |
Pharma Foods International Co., Ltd. (the "Company") hereby announces the execution, as of September 4, 2025, of a commitment line agreement incorporating financial covenants, as described below.
Purpose of this agreement
The Company confirms the renewal of its commitment line agreements dated September 6, 2022, and
December 22, 2023, which strengthens its financial foundation in healthcare, cosmetics, and pharmaceuticals and ensures funding for strategic growth, including expansion into agriculture and textiles.
Overview of the Loan Agreement with Financial Covenants
① Form of Agreement
Syndicated Commitment Line
② Total Amount
JPY 10 Billion
③ Date of Execution
September 4th, 2025
④ Arranger
The Bank of Kyoto, Ltd.
⑤ Contract Period
From September 9th, 2025 to September 8th, 2028
⑥ Interest Rate
Base Interest Rate plus Spread
⑦ Content of Collateral
None
LendersThe Bank of Kyoto, Ltd., Resona Bank, Limited, The San-in Godo Bank, Ltd., SBI Shinsei Bank, Limited., Kansai Mirai Bank, Limited, The Chiba Bank, Ltd., THE NISHI-NIPPON CITY BANK, LTD., The Hokuriku Bank, Ltd., The Iyo Bank, Ltd., The Bank of Toyama, Ltd., The Nanto Bank, Ltd., The Kyoto
Chuo Shinkin Bank, The Gunma Bank, Ltd., The Senshu Ikeda Bank, Ltd.
Content of Financial Covenants
① From the fiscal year ending July 2025 onward, the total amount of consolidated net assets on the balance sheet of each fiscal year's financial statements※ shall be maintained at not less than 75% of the total
amount of consolidated net assets reported on the balance sheet of the immediately preceding fiscal year.
② The consolidated ordinary profit/loss reported in the income statement for the fiscal year ending July 2025 shall not be a loss.
③ From the fiscal year ending July 2025 onward, consolidated ordinary profit/loss reported in the income
statements shall not be a loss for two consecutive fiscal years.
※Annual Financial Report, Semi-Annual Report, Extraordinary Report, Amendment Report.
Future Outlook
The effect of this agreement on the Company's financial results for the fiscal year ending July 2026 is expected to be limited. Should any new developments arise that could materially affect our performance, the Company will ensure timely disclosure.